查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1189816

瓣環成形術系統市場——增長、趨勢和預測 (2023-2028)

Annuloplasty System Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，瓣環成形術系統市場的複合年增長率預計為 4.2%。

COVID-19 大流行對瓣膜成形術系統市場產生了重大影響。 嚴格的封鎖和政府法規減少了心臟手術的數量。 在大流行期間，用於心臟修復手術的瓣環成形術系統使到醫院和診所接受手術的患者人數顯著下降。

例如，2022 年 2 月，發表在國家醫學圖書館雜誌上的一篇文章發現，印度在大流行期間選擇二尖瓣修復術的患者數量大幅下降。 此外，2022 年 3 月發表在國家醫學圖書館雜誌上的一篇論文發現，在 COVID-19 的第一次激增期間，美國的心臟手術數量急劇下降。 因此，COVID-19 爆發對其前身的市場增長產生了負面影響。 然而，在大流行後的情況下，它有望成為市場的推動力。

此外，老年人口的增加、開發可生物降解瓣環成形術系統的技術進步、越來越多地使用瓣環成形術系統修復主動脈瓣等是推動市場增長的一些主要因素。我們就是其中之一。 目前對血管成形術等微創手術的需求不斷增長。 例如，根據美國心臟協會2022年1月發布的心髒病和中風統計數據，美國冠狀動脈疾病的患病率約為7.2%，估計急性心肌梗死（AMI）的年發病率預計為到 2022 年上升。估計每 1,000 人中有 3.7 人。

瓣膜反流是一種常見於老年人的心臟瓣膜疾病，可由感染或組織退化引起。 血液滲入心臟深處，疾病就會惡化。 在這種情況下，如果不進行瓣環成形術或瓣膜置換術，心臟可能會受到永久性損傷。 此外，根據世界銀行2022年發布的數據，2020年英國65歲及以上人口將達到18.65%，而2021年為18.85%。 預計這一數字將繼續增加。 因此，老年人口的增加可能導致需要治療循環性出血的心血管疾病的增加。 預計這些因素將在預測期內推動市場增長。

此外，市場主要參與者的新產品發布和戰略活動對市場增長產生了積極影響。

例如，2021 年 1 月，經導管二尖瓣和三尖瓣修復和置換解決方案的開發商 Valcare Medical 宣布，它已經完成了 AMEND 瓣環成形術環的首次人體經房間隔遞送。我來了。 此外，2021 年 1 月，Micro Interventional Devices, Inc. 向公告機構提交了用於三尖瓣修復的 MIA-TTM 經皮三尖瓣瓣環成形術系統獲得 CE 標誌批准所需的技術文件。正在宣布。 因此，由於產品發布和合作夥伴關係，預計在預測期內市場將顯著增長。

因此，由於上述因素，預計所研究的市場將繼續增長。 然而，循環出血的高成本和熟練專業人員的短缺可能會阻礙市場增長。

主要市場趨勢

二尖瓣修復預計在預測期內增長

二尖瓣修復術是一種修復或更換心臟滲漏或僵硬的二尖瓣的手術。 二尖瓣位於左心室（左心房和左心室）之間。 二尖瓣修復可以通過心臟直視手術或微創心臟手術（瓣環成形術）來完成。 二尖瓣修復術最受醫生青睞，因為它對心臟的壓力較小。 此外，根據 2021 年 6 月發表在 BMJ 雜誌上的一篇論文，二尖瓣瓣環成形術治療繼發性心房二尖瓣反流後的預後與總體死亡率和二尖瓣反流有關。案例研究表明一個有利的結果，反映在瓣膜關閉不全的低復發率上。 由於二尖瓣成形術是最受醫生青睞的治療方法，因此有望在目標患者中普及，成為未來市場擴張的推動力。

此外，根據 2022 年 6 月發表在國家醫學圖書館雜誌上的一篇論文，對心髒病患者進行了個案研究。 這項研究表明，二尖瓣修復術的圍手術期死亡率低於二尖瓣置換術。 因此，二尖瓣修復相對於其他外科手術的日益優越性為該領域的未來增長創造了機會。

此外，市場主要參與者正在進行的研發活動對該細分市場的增長產生了積極影響。 例如，2021 年 4 月，市場領先的醫療技術和創新公司 LivaNova PLC 推出了美國 FDA 批准的增強心肌功能並減緩低射血性心力衰竭進展的突破性設備計劃。宣布第 300 例隨機化自主神經調節療法 (ANTHEM-HFrEF) 關鍵試驗中的患者。 此外，2021 年 9 月，Affluent Medical 宣布首次成功調整 Carios 二尖瓣環，該患者患有復發性嚴重術後二尖瓣反流。我來了。

因此，由於上述因素，預計二尖瓣修復領域在預測期內將出現顯著增長。

北美引領角膜成形術市場

由於技術先進的產品隨時可用以及患者對瓣膜修復手術和瓣膜成形術的高度認識，北美在市場上佔據主導地位。 美國老年人口的增加是促進北美研究市場增長的關鍵因素之一。

例如，根據經濟合作與發展組織（OECD）2022年發布的數據，2021年美國65歲及以上人口比例增至16.83%。 此外，根據人口事務研究所的數據，美國人口正在老齡化，男女之間的預期壽命差距正在縮小。 這些統計數據表明，該地區不斷增長的老年人口預計將推動該國的市場增長。

綜上所述，北美市場有望擴大。

競爭格局

隨著主要參與者在某些細分市場站穩腳跟，瓣環成形術系統市場正在整合。 競爭格局包括對少數具有市場份額的知名國際和本地公司的分析。 其中包括美敦力、雅培、Edwards Lifesciences Corporation、波士頓科學公司、Affluent Medical、BioStable Science & Engineering、LivaNova PLC、Coroneo、Genesee BioMedical、Medtentia International Ltd Oy、Micro Interventional Devices Incorporated、Valcare Medical。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 不斷增長的老年人口
    • 可生物降解瓣環成形術系統開發的技術進步
    • 越來越多地使用瓣環成形術系統進行主動脈瓣修復
  • 市場製約因素
    • 血管成形術的高昂費用
    • 缺乏熟練的專業人員
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 通過申請
    • 二尖瓣修復
    • 三尖瓣修復
    • 主動脈瓣修復
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 專科診所
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 世界其他地方

第六章競爭格局

  • 公司簡介
    • Medtronic
    • Abbott
    • Edwards Lifesciences Corporation
    • Boston Scientific Corporation
    • Affluent Medical
    • BioStable Science & Engineering
    • LivaNova PLC
    • Coroneo
    • Genesee BioMedical
    • Medtentia International Ltd Oy
    • Micro Interventional Devices Incorporated
    • Valcare Medical

第7章 市場機會與今後動向

簡介目錄
Product Code: 92949

The annuloplasty system market is expected to register a CAGR of 4.2% during the forecast period.

The COVID-19 pandemic had a substantial impact on the annuloplasty system market. The strict lockdowns and government regulations resulted in a decrease in the number of cardiac surgeries. The annuloplasty system is used in heart repair surgeries, and during the pandemic, the number of patients going to hospitals or clinics for surgeries decreased significantly.

For instance, according to an article published by the journal of the National Library of Medicine in February 2022, there was a significant drop in the number of patients opting for mitral valve repair during the pandemic in India. Furthermore, according to an article published in the journal of the National Library of Medicine in March 2022, the cardiac surgery volume decreased dramatically during the first surge of COVID-19 in United States. Thus, the COVID-19 outbreak negatively affected the market's growth in its preliminary phase. However, the market is expected to gain traction in the post-pandemic scenario.

Further, the rising geriatric population, technological advancements in the development of biodegradable annuloplasty systems, and increasing use of annuloplasty systems for aortic valve repair are among the major factors driving the growth of the market. Currently, the demand for minimally invasive procedures like annuloplasty is increasing. For instance, according to the heart disease and stroke statistics released by the American Heart Association in January 2022, the prevalence of coronary heart disease was around 7.2% in United States, and an estimated yearly incidence of acute myocardial infarction (AMI) is 3.7 in 1,000 individuals in 2022.

Heart valve regurgitation is a common heart valve disease in the elderly that may be caused by an infection or degeneration of the tissues. It causes blood to leak backward into the heart, and the condition is progressive. Annuloplasty or valve replacement must be done in such cases, or the heart can be permanently damaged. Moreover, according to the data published by Worldbank in 2022, 18.85% of the population in United Kingdom was aged more than 65 years in 2021, whereas 18.65% in 2020. This number is expected to increase in the future. Therefore, the rising geriatric population will increase the number of cardiovascular diseases that need annuloplasty treatment. These factors are expected to drive the growth of the market in the forecast period.

In addition, new product launches and strategic activities by major players in the market are positively affecting the market's growth.

For instance, in January 2021, Valcare Medical, developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announced that they had completed their first-in-human trans-septal delivery of the AMEND annuloplasty ring. Additionally, in January 2021, Micro Interventional Devices Incorporated announced that they had submitted the required technical documentation for CE Mark approval for its MIA-TTM Percutaneous Tricuspid Annuloplasty System for tricuspid valve repair to its notified body. Thus, due to product launches and partnerships, the market is expected to grow significantly in the forecast period.

Therefore, owing to the aforementioned factors, the market studied is anticipated to witness growth. However, the high cost of annuloplasty and the lack of skilled professionals are likely to impede the market growth.

Key Market Trends

Mitral Valve Repair is Expected to Witness Growth During the Forecast Period

Mitral valve repair is a type of surgery to fix or replace a leaky or stiff mitral valve in the heart. The mitral valve is between the left heart chambers (left atrium and left ventricle). Mitral valve repair may be done as open-heart or minimally invasive heart surgery (annuloplasty). Mitral valve repair is most commonly preferred by doctors as it puts less stress on the heart. Moreover, according to an article published in BMJ Journal in June 2021, a case study suggested that the prognosis following mitral valve annuloplasty to treat atrial secondary mitral regurgitation is good, as reflected by lower all-cause mortality and mitral regurgitation recurrence. As doctors most commonly prefer mitral valve repair, the adoption of this procedure is likely to increase among the target population, ultimately driving market growth.

In addition, according to an article published in the journal of the National Library of Medicine in June 2022, a case study was performed on heart disease patients. The study showed that mitral valve repair had lower perioperative mortality than mitral valve replacement. Thus, the increasing advantages of mitral valve repair over other procedures are creating opportunities for future growth of the segment.

Furthermore, continuous R&D activities by major players in the market are positively affecting the segment's growth. For instance, in April 2021, LivaNova PLC, a market-leading medical technology and innovation company, announced that they had randomized the 300th patient in the autonomic regulation therapy to enhance myocardial function and reduce the progression of heart failure with reduced ejection fraction (ANTHEM-HFrEF) pivotal study, which United States FDA approved under the Breakthrough Devices Program. Further, in September 2021, Affluent Medical announced the success of the first-ever Kalios mitral ring adjustment on a patient suffering from a post-operative recurrence of severe mitral insufficiency.

Therefore, the mitral valve repair segment is expected to witness significant growth during the forecast period due to the abovementioned factors.

North America is Dominating the Annuloplasty System Market

North America is dominating the market owing to factors such as the easy availability of technologically advanced products and high awareness among patients about valve repair surgeries or annuloplasty. An increase in the geriatric population in United States is among the key factors contributing to the growth of the market studied in North America.

For instance, according to the data from Organisation for Economic Co-operation and Development (OECD) published in 2022, the population aged 65 or older as a percentage of the total population increased to 16.83% in 2021 in United States. Furthermore, according to Population Reference Bureau, United States population is growing older, and the gender gap in life expectancy is narrowing. These statistics suggest that the rising geriatric population in the region is anticipated to drive market growth in the country.

Therefore, owing to the aforementioned factors, the market's growth is anticipated in the North America Region.

Competitive Landscape

The annuloplasty system market is consolidated as the major players have established themselves in specific market segments. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. This includes Medtronic, Abbott, Edwards Lifesciences Corporation, Boston Scientific Corporation, Affluent Medical, BioStable Science & Engineering, LivaNova PLC, Coroneo, Genesee BioMedical, Medtentia International Ltd Oy, Micro Interventional Devices Incorporated, Valcare Medical among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 Technological Advancements in the Development of Biodegradable Annuloplasty Systems
    • 4.2.3 Increasing Use of Annuloplasty Systems for Aortic Valve Repair
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Annuloplasty
    • 4.3.2 Lack of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Application
    • 5.1.1 Mitral Valve Repair
    • 5.1.2 Tricuspid Valve Repair
    • 5.1.3 Aortic Valve Repair
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Specialty Clinics
    • 5.2.4 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic
    • 6.1.2 Abbott
    • 6.1.3 Edwards Lifesciences Corporation
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Affluent Medical
    • 6.1.6 BioStable Science & Engineering
    • 6.1.7 LivaNova PLC
    • 6.1.8 Coroneo
    • 6.1.9 Genesee BioMedical
    • 6.1.10 Medtentia International Ltd Oy
    • 6.1.11 Micro Interventional Devices Incorporated
    • 6.1.12 Valcare Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS